GENERTI™ Biosystems Sdn. Bhd. undertakes the design, development, fabrication and commercialization of the INFOHaem Chip™ for Familial Hypercholesterolemia. The Company believes that it has a strong potential to successfully commercialize the product, making it a true global success. GENERTI™ has already identified and built extensive library for 72 other genetic disorders expressed in human blood as potential candidates for future development. GENERTI™ has Illumina Inc, the global technology leader in Microarray as partner to this project.The flagship project INFOHaem™ FH has undergone clinical validation with 300 study & control subjects at University Malaya Medical Centre (UMMC).

GENERTI™ Biosystems Sdn. Bhd. is also in the business of Molecular Screening Services, to provide molecular based predisposition, diagnostic, prognostic tests to the target healthcare sector, by adopting the most high end microarray technology platform (genotyping and gene expression) and known sciences today.  Molecular Screening is the analysis used to examine at a Subject’s genetic makeup (DNA, RNA, proteins, or other chemicals in cells that can indicate a genetic condition) to establish the Subject’s genetic predisposition, diagnosis, prognosis to certain diseases.

Genetic Predisposition Screening is the new line of healthcare measures for healthy Subjects in wellness and preventive medicine industry. Genetic Predisposition is defined as a latent susceptibility to disease at genetic level, which may be activated under certain condition/triggers. A Subject’s Genetic makeup is examined using Molecular based tool to establish the genetic predisposition towards certain condition/diseases such as Cancer, cardiovascular diseases etc.

Currently, INFOVALLEY is focusing on the provision of Molecular Screening Service for 12 types of Cancers. It is a genetic predisposition screening and establishment of Cancer Risk Profile through Clinico-Molecular Correlation for clinically healthy Subject from hospital, wellness centres and specialized laboratory. This enables the mapping of Genomics to phenomics, which provides greater scientific justification to the usual clinical condition.